This page contains information provided by Better Buildings & Better Plants Initiative partners. It is not the viewpoint of the U.S. Department of Energy.

MedImmune Improves Energy Performance at Maryland Facility

MedImmune, the global biologics research and development arm of AstraZeneca, improved energy performance at its Maryland facility by 8.5%.

Attachments:

MedImmune_case_study.pdf (2.49 MB)

Publication Date:

Wednesday, October 24, 2018

Published on: 12/27/2018